NVO
Novo Nordisk A/S
NYSE · Healthcare
—
(—)
NVO News3 articles
Novo Nordisk Rebounds as FDA Vows Crackdown on Wegovy Copycats
Novo Nordisk B shares surged 5.29% after Hims & Hers halted its $49 compounded version of Wegovy, with the FDA pledging action against unauthorized copycats. The stock remains down roughly 20% over five sessions amid pricing uncertainty.
FDA Crackdown on Compounded Weight-Loss Drugs Boosts Eli Lilly Shares
Eli Lilly's stock rose 3.7% after the FDA warned Hims & Hers to halt sales of a non-approved compounded GLP-1 weight-loss pill, signaling a regulatory clampdown that may support pricing for branded obesity drugs.
Novo Nordisk Shares Rebound as Hims Halts Wegovy Copycat After FDA Pressure
Novo Nordisk's Class B shares surged 5.3% after Hims & Hers discontinued its compounded Wegovy pill following U.S. regulatory warnings. The stock had dropped nearly 8% when the copycat launched.